
OUR WEBSITE IS CURRENTLY UNDERGOING A REBUILD AND WILL BE LAUNCHED SHORTLY.
DURING THIS PERIOD IF YOU WISH TO CONTACT US PLEASE USE THIS EMAIL
L3 Technology Limited
L3 Technology Limited (L3T), a privately held UK company, has developed and patented technologies for use in microfluidic applications. The Company’s primary focus is on developing an in-vitro diagnostic point of care (POC) platform that is suitable for use in a range of clinical settings; from hospital emergency rooms and intensive care units, to physician offices, wellness clinics and pharmacies through to home use. The platform has the ability to perform fluoresence and / or turbidimetric based assays.
Proof of concept studies have been completed to demonstrate the platform’s potential capabilities using assays for Total Cholesterol, Total Lipid, bacterial enzymes and other analytes. The Company is currently developing a hand-held reader and expects the new prototypes to be available for demonstration by October 2011.

Reaction Channels Reagent Depositions (100x) Reagent Card
Enabling Technologies and Know How